ArticleBMC medicine2023

First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations.

Xuan Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.